ProRx LLC FDA Record

Warning letters, Form 483s, inspections, recalls and 510(k) clearances

  • Latest inspection OAI · Sep 19, 2025
  • Last warning letter 2026
Inspections 2 2 OAI
Recalls 14 0 Class I (0%)
Warning letters 3 Latest Apr 7, 2026
510(k) clearances 0 None on file

ProRx LLC has 14 FDA recalls, 2 inspections, 0 510(k) clearances and 2 compliance actions on record. FDA has issued 3 warning letters to ProRx LLC, the most recent on Apr 7, 2026. FDA has published 2 Form 483s for ProRx LLC.

What these totals cover: FDA records filed under the name "ProRx LLC" and its spelling variant "Prorx".

Latest recall
D-0118-2026 · Class II · Oct 15, 2025
Latest inspection
Sep 19, 2025 · OAI

Summary

Record counts and when each FDA source was last refreshed
RecordsCountLast refreshedSource as ofStatus
Recalls14Nov 15, 2026File dated Nov 10, 2026Current
510(k) clearances0Nov 15, 2026File dated Nov 9, 2026Current
Inspections2Nov 17, 2026Newest record Nov 9, 2026Current
Compliance actions2Nov 2, 2026Newest record Oct 29, 2026Current

FDA record by year

ProRx LLC's FDA inspections, warning letters and recalls in each of the last 10 calendar years (2017 to 2026, 2026 so far).

ProRx LLC: FDA inspections per year

2017: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2018: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2019: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2020: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2021: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2022: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2023: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2024: 1 inspection (1 OAI), 1 warning letter, 7 recall records (0 Class I) 2025: 1 inspection (1 OAI), 0 warning letters, 7 recall records (0 Class I) 2026: 0 inspections (0 OAI), 1 warning letter, 0 recall records (0 Class I)
YearInspectionsOAIWarning lettersRecall recordsClass I
202600100
202511070
202411170
202300000
202200000
202100000
202000000
201900000
201800000
201700000

Inspections are counted by the date they ended, warning letters by the date FDA issued them and recall records by the recall start date. FDA lists one recall record per recalled product, so one recall event can add several.

Reviewing ProRx LLC as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check ProRx LLC yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

ProRx LLC FDA Warning Letters

3 warning letters from Dec 20, 2024 to Apr 7, 2026.

IssuedSubjectIssuing officeClose-out letter
Apr 7, 2026 · Letter on fda.gov Compounding Pharmacy/Adulterated Drug ProductsCenter for Drug Evaluation and Research (CDER)
Mar 4, 2025 · Letter on fda.gov Compounding Pharmacy/Adulterated Drug ProductsCenter for Drug Evaluation and Research (CDER)
Dec 20, 2024 · Record page

A warning letter is FDA's formal notice that a company has violated FDA requirements. Each date links to the letter on fda.gov where FDA has it online. Search the text of every letter with the FDA warning letter search.

ProRx LLC Form 483s

2 Form 483s published by FDA.

DateDocumentFEI
Sep 19, 2025 · Document on fda.gov 4833022250654
Aug 2, 2024 · Document on fda.gov 4833022250654

A Form 483 lists the observations FDA investigators made at the end of an inspection. FDA publishes some Form 483s in its reading room, and each date links to that document. Read the observations with the FDA 483 search.

Recent recalls

14 recall records from Aug 22, 2024 to Oct 15, 2025.

NumberClassProductDate
D-0118-2026Class IISemaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd…Oct 15, 2025
D-0117-2026Class IISemaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only…Oct 15, 2025
D-0115-2026Class IISemaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only…Oct 15, 2025
D-0114-2026Class IISemaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd…Oct 15, 2025
D-0119-2026Class IISemaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd…Oct 15, 2025
D-0120-2026Class IITirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd…Oct 15, 2025
D-0116-2026Class IISemaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only…Oct 15, 2025
D-0652-2024Class IISEMAGLUTIDE 5mg/2mL (2.5mg/mL), Rx Only 2 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by…Aug 22, 2024
D-0651-2024Class IITirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product…Aug 22, 2024
D-0656-2024Class IITIRZEPATIDE 60 mg/3mL (20/mg/mL), Rx Only, 3mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341…Aug 22, 2024
D-0654-2024Class IISemaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx…Aug 22, 2024
D-0653-2024Class IISEMAGLUTIDE 10mg/4mL (2.5mg/mL), 4 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX…Aug 22, 2024
D-0655-2024Class IITIRZEPATIDE 20 mg/2mL (10/mg/mL), Rx Only, 2mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341…Aug 22, 2024
D-0650-2024Class IISemaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx…Aug 22, 2024

Recent FDA inspections

2 inspections from Aug 2, 2024 to Sep 19, 2025.

DateSiteProductClassificationFEI
Sep 19, 2025Exton, PADrugsOfficial Action Indicated (OAI)3022250654
Aug 2, 2024Exton, PADrugsOfficial Action Indicated (OAI)3022250654
NAI
No objectionable conditions or practices were found during the inspection.
VAI
Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
OAI
Regulatory and/or administrative actions are recommended.

Look up the inspector observations behind these results with the FDA 483 search, or check for formal enforcement with the FDA warning letter search.

Compliance Actions

FDA's compliance actions data lists 2 compliance actions under ProRx LLC: warning letters, injunctions and seizures. None came from FDA's Center for Tobacco Products.

Most recent: Warning Letter, Apr 7, 2026.

The warning letters in this data are listed above, together with the letters FDA posts online; a letter found in both is shown once. Other actions are not listed on this page. Search them with the FDA warning letter search or browse all compliance actions.

FDA-inspected facilities

1 inspected site, newest inspection first.

FacilityLocationInspectionsLatest
FEI 3022250654Exton, PA2Sep 19, 2025

ProRx LLC and the FDA: common questions

Has ProRx LLC received an FDA warning letter?

Yes. FDA has issued 3 warning letters to ProRx LLC. The most recent is dated Apr 7, 2026, with the subject "Compounding Pharmacy/Adulterated Drug Products".

Has ProRx LLC received an FDA Form 483?

FDA has published 2 Form 483s for ProRx LLC in its reading room, the most recent dated Sep 19, 2025. FDA publishes some Form 483s, not all of them.

When did the FDA last inspect ProRx LLC?

The most recent FDA inspection on file ended Sep 19, 2025 at Exton, PA and was classified OAI. FDA has 2 inspections of ProRx LLC on file, 2 of them classified OAI (official action indicated).

Has ProRx LLC had an FDA recall?

Yes. ProRx LLC has 14 FDA recalls on record. The most recent started Oct 15, 2025.

Need more than this page shows? Ask about ProRx LLC in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.

Get a free API key

Prefer a PDF? Request a free supplier snapshot.

Is this your company or a supplier you list? Link to this FDA record from your site with a free button.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.